{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:34:26Z","timestamp":1782902066451,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2017JJ3250"],"award-info":[{"award-number":["2017JJ3250"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2019JJ40230"],"award-info":[{"award-number":["2019JJ40230"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["B2019034"],"award-info":[{"award-number":["B2019034"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Science and Technology of Health Commission of Hunan Province","award":["B2019035"],"award-info":[{"award-number":["B2019035"]}]},{"name":"Bethune Medical Scientific Research Foundation","award":["SCZ049BS"],"award-info":[{"award-number":["SCZ049BS"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Integrase inhibitors (INIs)-based antiretroviral therapies (ART) are more recommended than efavirenz (EFV)-based ART for people living with HIV\/AIDS (PLWHA). Yet, the advantage of integrase inhibitors in treating\u00a0TB\/HIV coinfection is uncertain. Therefore, the objective of this systematic review is to evaluate the effects and safety of INIs- versus EFV-based ART in TB\/HIV coinfection, and demonstrate the feasibility of the regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four electronic databases were systematically searched through September 2020. Fixed-effects models were used to calculate pooled effect size for all outcomes. The primary outcomes were virologic suppression and bacteriology suppression for INIs- versus EFV-based ART. Secondary outcomes included CD4<jats:sup>+<\/jats:sup> cell counts change from baseline, adherence and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three trials (including 672\u00a0TB\/HIV patients) were eligible. ART combining\u00a0INIs and EFV had similar effects for all outcomes, with none of the point estimates argued against the INIs-based ART on TB\/HIV patients. Compared to EFV-based ART as the reference group, the RR was 0.94 (95% CI 0.85 to 1.05) for virologic suppression, 1.00 (95% CI 0.95 to 1.05) for bacteriology suppression, 0.98 (95% CI 0.95 to 1.01) for adherence. The mean difference in CD4<jats:sup>+<\/jats:sup> cell counts increase between the two groups was 14.23 cells\/\u03bcl (95% CI 0\u2212 6.40 to 34.86). With regard to safety (adverse events, drug-related adverse events, discontinuation for drugs, grade 3\u20134 adverse events, IRIS (grade 3\u20134), and death), INIs-based regimen was broadly similar to EFV-based regimens. The analytical results in all sub-analyses of\u00a0raltegravir- (RAL) and dolutegravir (DTG) -based ART were valid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This meta-analysis demonstrates similar efficacy and safety of INIs-based ART compared with EFV-based ART. This finding supports INIs-based ART as a first-line treatment in TB\/HIV patients. The conclusions presented here still await further validation owing to insufficient data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-021-00348-w","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:16:39Z","timestamp":1620044199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB\/HIV coinfection: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuanlu","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijialong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"348_CR1","volume-title":"Three I\u2019s meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV","author":"WHO","year":"2008","unstructured":"WHO. Three I\u2019s meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO; 2008."},{"issue":"2","key":"348_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00002030-200101260-00002","volume":"15","author":"YD Mukadi","year":"2001","unstructured":"Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15(2):143\u201352.","journal-title":"AIDS"},{"issue":"4","key":"348_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijid.2007.02.001","volume":"11","author":"JF Djoba Siawaya","year":"2007","unstructured":"Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV\/TB infection. Int J Infect Dis. 2007;11(4):289\u201399.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"348_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"1","key":"348_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-016-0106-y","volume":"13","author":"W Manosuthi","year":"2016","unstructured":"Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13(1):1\u20132.","journal-title":"AIDS Res Ther"},{"key":"348_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12981-016-0106-y","volume":"13","author":"W Manosuthi","year":"2016","unstructured":"Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13:22.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"348_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300(5):530\u20139.","journal-title":"JAMA"},{"issue":"5","key":"348_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","volume":"9","author":"W Manosuthi","year":"2008","unstructured":"Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9(5):294\u20139.","journal-title":"HIV Med"},{"issue":"7","key":"348_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/cid\/cir447","volume":"53","author":"S Swaminathan","year":"2011","unstructured":"Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53(7):716\u201324.","journal-title":"Clin Infect Dis"},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2014.04.020","volume":"25","author":"HY Jiang","year":"2014","unstructured":"Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2014;25:130\u20135.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"348_CR11","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/bcp.13600","volume":"84","author":"D Atwine","year":"2018","unstructured":"Atwine D, Bonnet M, Taburet AM. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review. Br J Clin Pharmacol. 2018;84(8):1641\u201358.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"348_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.dmpk.2015.07.002","volume":"31","author":"DY Cho","year":"2016","unstructured":"Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, et al. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metab Pharmacokinet. 2016;31(2):107\u201316.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"348_CR13","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/jcph.756","volume":"56","author":"A Habtewold","year":"2016","unstructured":"Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, et al. Long-term effect of rifampicin-based anti-TB regimen coadministration on the pharmacokinetic parameters of efavirenz and 8-hydroxy-efavirenz in Ethiopian patients. J Clin Pharmacol. 2016;56(12):1538\u201349.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"348_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1517\/17425250903393752","volume":"6","author":"A Kwara","year":"2010","unstructured":"Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol. 2010;6(1):55\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"348_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1365-2125.2010.03883.x","volume":"71","author":"D Reki\u0107","year":"2011","unstructured":"Reki\u0107 D, R\u00f6shammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol. 2011;71(4):536\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"348_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.5414\/CP202079","volume":"52","author":"J Liu","year":"2014","unstructured":"Liu J, Chan-Tack KM, Jadhav P, Seo S, Robertson SM, Kraft J, et al. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Int J Clin Pharmacol Ther. 2014;52(6):446\u201353.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"9231835","DOI":"10.1155\/2018\/9231835","volume":"2018","author":"MS Xavier","year":"2018","unstructured":"Xavier MS, Trajman A, Schmaltz CAS, Sant\u2019anna FM, Maia IR, Hadad DJ, et al. Daily 800 mg versus 600 mg efavirenz for HIV patients treating tuberculosis with a rifampicin-based regimen: an Open Label Randomized Controlled Trial. Biomed Res Int. 2018;2018:9231835.","journal-title":"Biomed Res Int"},{"issue":"1","key":"348_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12879-018-3077-x","volume":"18","author":"Y Caro-Vega","year":"2018","unstructured":"Caro-Vega Y, Schultze A, Efsen AM, Post FA, Panteleev A, Skrahin A, et al. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. BMC Infect Dis. 2018;18(1):191.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"348_CR19","doi-asserted-by":"publisher","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","volume":"6","author":"G Yimer","year":"2011","unstructured":"Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE. 2011;6(12):e27810.","journal-title":"PLoS ONE"},{"issue":"3","key":"348_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/cid\/cix335","volume":"65","author":"PM Murnane","year":"2017","unstructured":"Murnane PM, Strehlau R, Shiau S, Patel F, Mbete N, Hunt G, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in human immunodeficiency virus-infected children exposed to nevirapine: long-term outcomes of a Randomized Trial. Clin Infect Dis. 2017;65(3):477\u201385.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"348_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12916-017-0842-4","volume":"15","author":"DL Dahourou","year":"2017","unstructured":"Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, et al. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and C\u00f4te d\u2019Ivoire: the MONOD ANRS 12206 non-inferiority Randomised Trial. BMC Med. 2017;15(1):85.","journal-title":"BMC Med"},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2050-6511-15-61","volume":"15","author":"S Naiker","year":"2014","unstructured":"Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014;15:61.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"348_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12879-020-05169-2","volume":"20","author":"S Kouanda","year":"2020","unstructured":"Kouanda S, Ouedraogo HG, Cisse K, Compaor\u00e9 TR, Sulis G, Diagbouga S, et al. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir\/ritonavir in African HIV and tuberculosis co-infected adult patients. BMC Infect Dis. 2020;20(1):449.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"348_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s15010-020-01469-6","volume":"48","author":"M Stecher","year":"2020","unstructured":"Stecher M, Schommers P, Kollan C, Stoll M, Kuhlendahl F, Stellbrink HJ, et al. Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005\u20132017. Infection. 2020;48(5):723\u201333.","journal-title":"Infection"},{"key":"348_CR25","unstructured":"UNAIDS. New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries at reduced price. https:\/\/www.unaidsorg\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2017\/september\/20170921_TLD"},{"issue":"19","key":"348_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guti\u00e9rrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"348_CR27","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/cid\/civ477","volume":"61","author":"AM Taburet","year":"2015","unstructured":"Taburet AM, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015;61(8):1328\u201335.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"348_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"348_CR29","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","volume":"5","author":"J Dorward","year":"2018","unstructured":"Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5(7):e400\u20134.","journal-title":"Lancet HIV"},{"issue":"12","key":"348_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","volume":"32","author":"M Vitoria","year":"2018","unstructured":"Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551\u201361.","journal-title":"AIDS"},{"key":"348_CR31","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"key":"348_CR32","doi-asserted-by":"publisher","first-page":"l4179","DOI":"10.1136\/bmj.l4179","volume":"366","author":"Q Feng","year":"2019","unstructured":"Feng Q, Zhou A, Zou H, Ingle S, May MT, Cai W, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of Randomised Controlled Trials. BMJ. 2019;366:l4179.","journal-title":"BMJ"},{"key":"348_CR33","unstructured":"US DHSS F, CDER. Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry. 2015; https:\/\/www.fdagov\/media\/86284\/download. Accessed 9 Mar 2021."},{"key":"348_CR34","unstructured":"WHO. Tuberculosis care with TB-HIV co-management. 2007; https:\/\/www.whoint\/hiv\/pub\/imai\/TB_HIVModule230507pdf?ua=1[Accessed 9 October 2020]."},{"key":"348_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"348_CR36","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"348_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","volume":"14","author":"B Grinsztejn","year":"2014","unstructured":"Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, Randomised Trial. Lancet Infect Dis. 2014;14(6):459\u201367.","journal-title":"Lancet Infect Dis"},{"key":"348_CR38","unstructured":"Nct. Efficacy and safety of 2 raltegravir doses in Naive HIV-1-infected patients receiving rifampin for active tuberculosis. https:\/\/clinicaltrials.gov\/show\/NCT008223152009."},{"key":"348_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30869-0","author":"N De Castro","year":"2021","unstructured":"De Castro N, Marcy O, Chazallon C, Messou E, Eholi\u00e9 S, N\u2019Takpe JB, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(20)30869-0.","journal-title":"Lancet Infect Dis"},{"key":"348_CR40","unstructured":"Nct. Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis. 2014. https:\/\/clinicaltrials.gov\/show\/nct02273765"},{"issue":"4","key":"348_CR41","first-page":"549","volume":"70","author":"KE Dooley","year":"2020","unstructured":"Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, Randomized Trial. Clin Infect Dis. 2020;70(4):549\u201356.","journal-title":"Clin Infect Dis"},{"key":"348_CR42","unstructured":"Nct. Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection. 2014. https:\/\/clinicaltrials.gov\/show\/nct02178592"},{"issue":"2","key":"348_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/QAI.0000000000002126","volume":"82","author":"C Modongo","year":"2019","unstructured":"Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G, et al. Clinical and virological outcomes of TB\/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"348_CR44","first-page":"273","volume":"28","author":"REG Pinho","year":"2020","unstructured":"Pinho REG, Pascom ARP, Alves K, Oliveira PB, Menezes AI, Perini FB, et al. CD4 count and viral load dynamics under different art regimens in HIV\/TB coinfection. Topics Antiviral Med. 2020;28(1):273.","journal-title":"Topics Antiviral Med"},{"issue":"10","key":"348_CR45","doi-asserted-by":"publisher","first-page":"e0162775","DOI":"10.1371\/journal.pone.0162775","volume":"11","author":"GW Rutherford","year":"2016","unstructured":"Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS ONE. 2016;11(10):e0162775.","journal-title":"PLoS ONE"},{"key":"348_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2334-14-125","volume":"14","author":"A Mihret","year":"2014","unstructured":"Mihret A, Abebe M, Bekele Y, Aseffa A, Walzl G, Howe R. Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis. 2014;14:125.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"348_CR47","doi-asserted-by":"publisher","first-page":"e00115518","DOI":"10.1590\/0102-311x00115518","volume":"35","author":"TS Cardoso","year":"2019","unstructured":"Cardoso TS, Costa JO, Reis EA, Silveira MR, Bonolo PF, Santos SFD, et al. Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens. Cad Saude Publica. 2019;35(9):e00115518.","journal-title":"Cad Saude Publica"},{"key":"348_CR48","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3389\/fphar.2019.01225","volume":"10","author":"Y Huang","year":"2019","unstructured":"Huang Y, Huang X, Chen H, Wu H, Chen Y. Efficacy and safety of raltegravir-based dual therapy in AIDS patients: a meta-analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1225.","journal-title":"Front Pharmacol"},{"issue":"1","key":"348_CR49","first-page":"313s","volume":"25","author":"M Dutertre","year":"2017","unstructured":"Dutertre M, Cuzin L, Pugli\u00e8se P, Joly V, Valantin MA, Cotte L, et al. Initiation of ART based on integrase inhibitors increases the risk of IRIS. Topics Antiviral Med. 2017;25(1):313s\u20134s.","journal-title":"Topics Antiviral Med"},{"issue":"9","key":"348_CR50","doi-asserted-by":"publisher","first-page":"e0222229","DOI":"10.1371\/journal.pone.0222229","volume":"14","author":"M Cruciani","year":"2019","unstructured":"Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS ONE. 2019;14(9):e0222229.","journal-title":"PLoS ONE"},{"issue":"1","key":"348_CR51","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","volume":"19","author":"SJ Snedecor","year":"2019","unstructured":"Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):484.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"348_CR52","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"3","author":"S Kanters","year":"2016","unstructured":"Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510\u201320.","journal-title":"Lancet HIV"},{"issue":"1","key":"348_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12981-016-0115-x","volume":"13","author":"J Jiang","year":"2016","unstructured":"Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir(DTG, S\/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther. 2016;13(1):30.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"348_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-020-4132-7","volume":"21","author":"R Nabisere","year":"2020","unstructured":"Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, et al. Pharmacokinetics, SAfety\/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials. 2020;21(1):1\u20139.","journal-title":"Trials"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00348-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T04:05:42Z","timestamp":1626840342000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00348-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00348-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have disclosed that they have no significant relationships with, or financial interest in, any other commercial companies pertaining to this article. CQ received grants from the Natural Science Foundation of Hunan Province, China (2017JJ3250), and Project of Science and Technology of Health Commission of Hunan Province, China (B2019034); XZ received grants from the Natural Science Foundation of Hunan Province, China (2019JJ40230), and Project of Science and Technology of Health Commission of Hunan Province, China (B2019035); LY received grants from the Bethune Medical Scientific Research Foundation (SCZ049BS); the other authors had no financial relationships with any organisations; no other relationship or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}